Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus lenvatinib versus lenvatinib first-line therapy for advanced primary liver cancer
ChiCTR2100052460Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of camrelizumab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Overall survival. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
camrelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100052460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052460.